Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide and tirzepatide, have rapidly reshaped the management of type 2 diabetes and obesity. Their ability to lower blood glucose, reduce body weight, and modulate appetite has been hailed as a therapeutic breakthrough. But as these agents move from niche to mainstream, clinicians across disciplines are discovering their broader […]
Recent Posts
- Why Every Dentist Should Understand Generative AI and Bloom’s Taxonomy
- One-Hour Molecular Brush Biopsy Could Transform Oral Cancer Screening
- Virginia’s New Dental Scaling Law: What It Means for Dental Hygienists, Dental Assistants, and Patient Safety
- Why Orthodontists Are No Longer America’s Highest-Paid Professionals
- MDS Students Must Maintain 80% Biometric Attendance, Says NDC
Archives